0000000000466862

AUTHOR

Ke X. Szeto

showing 2 related works from this author

IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysin…

2016

Three Physiologically Based Pharmacokinetic software packages (GI-Sim, Simcyp® Simulator, and GastroPlus™) were evaluated as part of the Innovative Medicine Initiative Oral Biopharmaceutics Tools project (OrBiTo) during a blinded “bottom-up” anticipation of human pharmacokinetics. After data analysis of the predicted vs. measured pharmacokinetics parameters, it was found that oral bioavailability (Foral) was underpredicted for compounds with low permeability, suggesting improper estimates of intestinal surface area, colonic absorption and/or lack of intestinal transporter information. Foral was also underpredicted for acidic compounds, suggesting overestimation of impact of ionisation on pe…

Physiologically based pharmacokinetic modellingIn silicoDrug Evaluation PreclinicalAdministration OralPharmaceutical Science02 engineering and technologyPharmacologyModels Biological030226 pharmacology & pharmacyBiopharmaceutics03 medical and health sciences0302 clinical medicineLow permeabilityHumansComputer SimulationChemistryBiopharmaceutics021001 nanoscience & nanotechnologyBioavailabilityIntestinal AbsorptionPharmaceutical PreparationsColonic absorptionSystem parametersIntestinal surfaceBiochemical engineering0210 nano-technologyForecasting
researchProduct

IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and ov…

2016

Orally administered drugs are subject to a number of barriers impacting bioavailability (Foral), causing challenges during drug and formulation development. Physiologically-based pharmacokinetic (PBPK) modelling can help during drug and formulation development by providing quantitative predictions through a systems approach. The performance of three available PBPK software packages (GI-Sim, Simcyp®, and GastroPlus™) were evaluated by comparing simulated and observed pharmacokinetic (PK) parameters.Since the availability of input parameters was heterogeneous and highly variable, caution is required when interpreting the results of this exercise. Additionally, this prospective simulation exer…

Physiologically based pharmacokinetic modellingChemistryBiopharmaceuticsDrug Evaluation PreclinicalArea under the curveAdministration OralPharmaceutical ScienceModels Biological030226 pharmacology & pharmacyBiopharmaceuticsBioavailabilityClinical studyToxicology03 medical and health sciences0302 clinical medicineIntestinal AbsorptionPharmaceutical PreparationsPharmacokineticsCompounding030220 oncology & carcinogenesisStatisticsHumansComputer SimulationImmediate releaseForecastingEuropean Journal of Pharmaceutical Sciences
researchProduct